A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India

NCT01212133 · Completed

Last updated 2026-05-28

This study monitored the safety of the diabetes medication liraglutide in adults with type 2 diabetes in India by tracking serious side effects during the trial.

Status Completed The study has finished.

Type Observational

Participants 1,386 people

Who can join all sexes

Timeline Started 2010-11 · est. completion 2012-04

Where 1 site · India

What this study is testing ClinicalTrials.gov NCT01212133 ↗

Description as written by the study sponsor.

This study is conducted in Asia. The aim of this study is to evaluate the safety and effectiveness of liraglutide in subjects with type 2 diabetes mellitus.

Treatments tested

liraglutide Drug

Self-administered subcutaneously (under the skin) once daily at any time, independent of meals, in the abdomen, thigh or upper arm.

Main thing measured	The number of serious adverse drug reactions (SADRs) during the study period
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01212133 ↗